These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 22660440

  • 1. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients.
    Han N, Yun HY, Hong JY, Kim IW, Ji E, Hong SH, Kim YS, Ha J, Shin WG, Oh JM.
    Eur J Clin Pharmacol; 2013 Jan; 69(1):53-63. PubMed ID: 22660440
    [Abstract] [Full Text] [Related]

  • 2. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
    Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F.
    Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
    [Abstract] [Full Text] [Related]

  • 3. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients.
    Zhu L, Yang J, Zhang Y, Jing Y, Zhang Y, Li G.
    Xenobiotica; 2015 Sep; 45(9):840-6. PubMed ID: 25869250
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of CYP3A5, ABCB1 and POR*28 polymorphisms on pharmacokinetics of tacrolimus in the early period after renal transplantation.
    Ling J, Dong LL, Yang XP, Qian Q, Jiang Y, Zou SL, Hu N.
    Xenobiotica; 2020 Dec; 50(12):1501-1509. PubMed ID: 32453653
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.
    Bergmann TK, Hennig S, Barraclough KA, Isbel NM, Staatz CE.
    Ther Drug Monit; 2014 Feb; 36(1):62-70. PubMed ID: 24089074
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients.
    Kim IW, Moon YJ, Ji E, Kim KI, Han N, Kim SJ, Shin WG, Ha J, Yoon JH, Lee HS, Oh JM.
    Eur J Clin Pharmacol; 2012 May; 68(5):657-69. PubMed ID: 22183771
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population.
    Rahsaz M, Azarpira N, Nikeghbalian S, Aghdaie MH, Geramizadeh B, Moini M, Banihashemi M, Darai M, Malekpour Z, Malekhosseini SA.
    Exp Clin Transplant; 2012 Feb; 10(1):24-9. PubMed ID: 22309416
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.